Bluebird bio — European Hematology Association (EHA) Congress 2014
26 slides from Bluebird bio's conference presentation, Jun 16, 2014

Slide 1: Making Hope A Reality
Making Hope A Reality Nasdaq : BLUE June 16, 2014 Exhibit 99.2

Slide 2: Forward Looking Statement
Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue

Slide 3: Summary - Key Messages
Summary - Key Messages Potential for one - time transformative treatments for severe genetic and orphan diseases Encouraging clinical data in beta-thalassemia major patients Promising proof of concept data in CCALD patients Industrialized platform across people, production, development and deploymen

Slide 4: bluebird Pipeline
bluebird Pipeline Hematologic/Solid Tumors Undisclosed Products Program Area Preclinical Phase I/II Phase II/III Rights b - thalassemia/SCD (France) – HGB-205 Study** b - thalassemia (U.S.) – Northstar Study** Sickle Cell Disease (U.S.) – HGB-206 Study Childhood Cerebral ALD – Starbeam Study* CNS Di

Slide 5: Improving Gene Therapy for Thalassemia Major: Initial Results from Study HGB-205
IMPROVING GENE THERAPY FOR - THALASSEMIA MAJOR: INITIAL RESULTS FROM STUDY HGB-205 M. Cavazzana, JA Ribeil*, E. Payen*, F. Suarez, O. Negre, Y. Beuzard, F. Touzot, R. Cavallesco, F. Lefrere, S. Chretien, P. Bourget, F. Monpoux, C. Pondarre, B. Neven, F. Bushman, M. Schmidt, C. von Kalle, L. Sandler,

Slide 6: Epidemiology of hemoglobin disorders
Epidemiology of hemoglobin disorders The hemoglobinopathies are the most prevalent monogenetic disorders in the world – 7% of global population carry an abnormal hemoglobin gene Between 300,000 – 400,00 babies are born each year with a serious hemoglobin disorder • >40,000 with -thalassemia major/Hb

Slide 7: Beta-thalassemia major is a serious disease potentially amenable to gene therapy
-thalassemia major is a serious disease potentially amenable to gene therapy Study Lentiviral vector Current status Only curative approach is allogeneic HSCT, but complicated by: difficulty in finding well-matched donors graft versus host disease prolonged immunosuppression At EHA we report data fro

Slide 8: Identical study design for both gene therapy trials
Identical study design for both gene therapy trials • Key eligibility: • b - Thalassemia major ( 100 mls pRBCs/kg/year) • Subjects with severe sickle cell disease are also eligible; none treated to date • No HLA-matched sibling donor HSC mobilization then apheresis Myeloablation with IV busulfan Inf

Slide 9: HPV569 lentiviral vector used in Study
HPV569 lentiviral vector used in Study 1 Globin production is under transcriptional control of an erythroid - specific promoter and enhancer R U5 HIV U3 RRE cPPT pA gag 3’enh/pA Globin LCR U3 R A-T87Q - globin allows for monitoring of protein levels produced using HPLC Human -globin gene A-T87Q cHS4

Slide 10: Study characteristics of included subjects
Study 1 – characteristics of included subjects Subject Outcome Subject 3 Subject 4 • No AEs related to drug product, including no RCL nor malignancy Not treated Low number of stem cells infused, no engraftment, received rescue cells Engrafted, 6 years follow-up Engrafted, 2 years follow-up Age Genot

Slide 11: Study: hemoglobin concentrations
Study 1 : hemoglobin concentrations • Subject 3 : stable levels of b A-T87Q –globin beginning at Month 18, transfusion independent by Month 12 . Producing 2.7 g/dL of b A-T87Q -globin at years. • Subject 4 : minimal levels of b A-T87Q -globin post-treatment, transfusion dependent. Producing 0.4 g/dL

Slide 12: BB305 lentiviral vector used in Study
BB305 lentiviral vector used in Study 2 • Improvements made in vector design, vector manufacturing process, and drug product manufacturing, including: Study 2: Study 1: • CMV promoter to drive vector production ( aim to increase vector titer ) • cHS4 insulator elements were removed ( aim to increase

Slide 13: Improvements in BB305 vector design and manufacturing increase transduction efficiency in vitro
Improvements in BB305 vector design and manufacturing process increase transduction efficiency in vitro • Mean VCN was 2- to 3-fold higher in transduced human CD34 + cells • b A-T87Q –globin was produced at a 2-fold higher level in differentiated erythroid lineage cells

Slide 14: Study: characteristics of included subjects (to date)
Study 2 : characteristics of included subjects (to date) Subject 1 Subject 2 Age at Enrollment Genotype b / b E b / b E CD34 + VCN 1.5 2.1 CD34 + cell dose (x 10 /kg) 8.9 13.6

Slide 15: Study: Safety
Study 2 : Safety Subject 1 Subject 2 Follow up period 4.5 months 2 months Day of neutrophil engraftment ANC > 500/µL Day 13 Day 15 Day of platelet engraftment Unsupported platelet count > 20,000/µL Day 17 Day 24 Non-laboratory Grade 3 AEs Mucositis Mucositis SAEs occurring Day 0 None None Insertion

Slide 16: Mean VCN
Mean VCN 1.5 0.5 Subject 3 Subject 4 | |Subject 1 Hi subject 2 - a ya Lega ee Tes wne 23 45 6 7 8 9 10 11 12 bluebirdbio"

Slide 17: In study 2, early and high production of A-T87Q globin resulting in rapid transfusion-independence
In study 2, early and high production of A-T87Q -globin resulting in rapid transfusion-independence at near normal Hb levels in both patients • Subject 1 : producing 6.6 g/dL of b A-T87Q -globin at 4.5 months • Subject 2: producing 4.2 g/dL of b A-T87Q -globin at 2 months

Slide 18: Kinetics of A-T87Q expression and transfusion independence
Kinetics of A-T87Q expression and transfusion independence RBC transfusion Independence Study 2 Study 1 • In Study 2, rapid production of therapeutic globin (weeks as opposed to one year) • Both subjects in Study 2 have near-normal hemoglobin levels without transfusion support (neither subject has r

Slide 19: Conclusions
Conclusions • BB305 lentiviral vector and improved manufacturing process produce superior transduction efficiency as compared with HPV569 • With BB305 lentiviral vector in Study 2, neither subject has received a transfusion since the second week post transplantation • Production of b A-T87Q -globin

Slide 20: Evidence for why BB305 globin may work for sickle cell disease
Evidence for why BB305 globin may work for sickle cell disease • BB305 globin incorporates an anti- sickling amino acid that is found in fetal hemoglobin (glutamine at position 87) • Anti-sickling activity of b A-T87Q -globin has been demonstrated in a mouse model of SCD (Science 2001) • Elevated fe

Slide 21: Ongoing Studies using BB305 lentiviral vector
Ongoing Studies using BB305 lentiviral vector Study Centers Indication Planned subjects Current Status HGB-205 (trial reported today) 1 in France 4 subjects enrolled 2 subjects treated to date Northstar Study (HGB-204) 4 in US 1 in Australia 1 in Thailand 6 subjects enrolled 1 subject treated to dat

Slide 22: Recent and Upcoming News Flow
Recent and Upcoming News Flow 2013 2015 2014 Enroll first SCD patient in HGB-205 or HGB-206 (2014) Preliminary Thal Northstar & HGB-205 data (late 2014) Various clinical publications Signed global Oncology collaboration with Celgene Completed IPO Initiated phase II/III Starbeam Study Initiated two p

Slide 23: bluebird bio
bluebirdbior

Slide 24: bluebird bio
bluebirdbior

Slide 25: Study (LG001): Safety
Study 1 (LG001) : Safety Subject 3 Subject 4 • No AEs related to drug product, including no RCL nor malignancy Follow-up period 6 years 2 years Day of neutrophil engraftment ANC > 500/µL Day 27 Day 19 Day of platelet engraftment Unsupported platelet count > 20,000/µL Day 40 Day 130 Non-laboratory Gr

Slide 26: Subject (LG001): prominence of HMGA2 clone decreasing over time
Subject 3 (LG001) : prominence of HMGA2 clone decreasing over time • By Year 5, SPATS2 and ZZEF1 have replaced HMGA2 as the most common clones identified by LAM-PCR • In spite of decrease in HMGA2 clone, therapeutic effect has been maintained • No hematological or clinical effects of the HMGA2 clone
Source: SEC EDGAR · 8-K filed Jun 16, 2014
More decks from Bluebird bio Inc
J.P. Morgan Healthcare Conference 202423 slides · Jan 8, 2024
Corporate Update (December 2023)17 slides · Dec 11, 2023
Q2 2023 Earnings Presentation16 slides · Aug 8, 2023
Investor Presentation (July 2023)27 slides · Jul 12, 2023
Investor Presentation (June 2023)27 slides · Jun 12, 2023
J.P. Morgan Healthcare Conference 202329 slides · Jan 9, 2023